Intraparty disagreements over mifepristone cause pause in spending bill agreement until August recess ends; Officials urge the FDA to regulate cannabidiol as a dietary supplement; State medical boards tasked with protecting Americans frequently failed to stop doctors for COVID-19 misinformation.
Republican Disagreements Halt Spending Bill
Intraparty friction over the abortion pill mifepristone have delayed a plan for House votes on Friday and led GOP heads to push legislation funding the FDA until August recess ends, reported The Hill. The spending bill would also fund the Department of Agriculture and contains a provision to constrict restrictions surrounding access to mifepristone, which would nullify the agency’s decision to permit the drug to be dispensed through mail and retail pharmacies.
Officials Urge FDA to Regulate Cannabidiol
Officials and hemp advocates pressed the FDA to quickly regulate cannabidiol (CBD) products as dietary supplements at a House subcommittee hearing Thursday, according to Bloomberg Law. CBD products can’t be sold or regulated as dietary supplements yet because of CBD’s intrinsic risk profile and currently incomplete risk-management resources. Customer safeguards in the Federal Food, Drug and Cosmetic Act would apply to CBD products if they were regulated as dietary supplements, including adverse event reporting and possible child-proof packaging requirements.
Doctors Spreading COVID-19 Misinformation Rarely Punished
Doctors who endangered patients’ lives by pushing medical misinformation during the COVID-19 pandemic and its aftermath have not encountered sufficient repercussions, according to a Washington Post analysis of disciplinary records from medical boards in every state, reported The Washington Post. These medical boards, assigned with protecting the American public, frequently failed to stop doctors who went against medical consensus and prescribed treatments not approved for COVID-19 or who misled patients about masks and vaccines, found the investigation. Presently, no organization monitors how many doctors have been punished for spreading COVID-19 misinformation.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More